The Feds are signaling that pharma firms must do much more self-policing regarding their marketing practices—including those involving meetings—or risk federal prosecution under anti-kickback regulations. Specifically, the government is targeting the provision of financial incentives to healthcare professionals to prescribe or recommend particular drugs, or to switch patients from one medicine to another. The Department of Health and Human Services (HHS) Inspector General Janet Rehnquist ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock the Government Cracks Down on Pharma Industry, you'll also gain access to exclusive premium content.

Already registered? here.